XPeng Completes Production of 10,000 Units of P7 Smart EV Sedan
20.10.2020 11:00:00 EEST | Business Wire | Press release
XPeng Inc. (NYSE: XPEV) today completed the production of 10,000 units of the P7 smart EV sedan, its flagship model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005536/en/
The 10,000th P7 completed production at XPeng Zhaoqing factory (Photo: Business Wire)
The 10,000th P7 rolled off the production line from Xpeng’s self-built wholly-owned factory in Zhaoqing, Guangdong Province on Oct 20, 2020.
“Today sees us achieving the 10,000th unit production target earlier than expected. We delivered on our promise to bring high-quality smart EVs to meet our customer demand,” said He Xiaopeng, Chairman and CEO of XPeng at a ceremony in Zhaoqing.
The completion of 10,000 P7s reinforces XPeng’s position as a leading smart EV brand, demonstrating its strong capability in supply chain management, smart manufacturing and quality control, Chairman He Xiaopeng said.
The P7 smart EV sports sedan is designed and built with four goals: drive further and smarter, charge quicker, accelerate faster and control smoother. It offers an unrivalled combination of elegance, style and comfort with cutting-edge autonomous driving, voice interaction and powertrain technology, to deliver an unparalleled driving experience. The P7’s chassis was jointly developed with a luxury sports-style German engineering brand.
At 706km NEDC, the rear-wheel drive super-long range version has the longest driving range among production EVs in China. The P7’s in-house designed electric drive system - equipped with the German Infineon 950 IGBT module - provides a maximum motor efficiency of 97.5%. The 110mm height ultra-thin high-performance battery pack reaches 170Wh/kg energy density to deliver close to 81kWh of power with super-low drag coefficient of Cd0.236.
The Zhaoqing plant, birthplace of the P7, was built over a period of 15 months. The factory received the official production license from China’s Ministry of Industry and Information Technology on May 19 this year and completed the production of 10,000 P7s within 160 days, a record among new EV markers in China.
“The Smart EV market in China is at a crossroads, where companies focusing on differentiated products and quality services stand out from the rest, and we see it an irreversible trend,” CEO He Xiaopeng added.
For more P7 videos and images please visit: https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio
Find the pictures and videos about the factory here: https://drive.google.com/drive/folders/1RzxP_eVWDWwVdnfaYTt01G7hn3F-ZZeS?usp=sharing
Follow us on social media for latest Xpeng news:
Facebook
Twitter
LinkedIn
YouTube
Instagram
About XPeng
XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley, and San Diego in the U.S. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005536/en/
Contact information
For further information, please contact Marie Cheung: Email: mariecheung@xiaopeng.com
Mobile: (+852) 9750 5170 / (+86) 1550 7577 546
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom